Company intelligence

CLDX

Celldex Therapeutics, Inc. · NASDAQ · Healthcare

Price$39.18+6.18% · +$2.28

Market cap2.61BEquity value

P / E-9.2Trailing ratio

Volume1MLatest session

Market data

CLDX price chart

TradingView

Related signals

1 min delayed

Browse public CLDX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CLDXJul 21, 2026-2.50% since signal

Celldex PN Phase 2 failure clouds barzolvolimab's CSU path

Celldex reported Phase 2 PN results for barzolvolimab did not meet the primary or key secondary endpoints, leading to PN discontinuation despite a favorable safety profile and robust mast cell depletion. Phase 3 CSU topline data remain on track for Sept/Oct 2026, with Phase 3 SD and ColdU enrollment continuing and Phase 2 AD data expected late 2026. The news adds near-term uncertainty for CLDX until CSU results.

View signal analysis

CLDXAug 20, 2025+0.89% since signal

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

CLDX announced topline Phase 2 results for barzolvolimab in EoE. While the primary endpoint was met, EoE symptoms showed no improvement. Barzolvolimab has a favorable safety profile but will not advance in EoE. The stock dropped 11.12% following the announcement to $21.35. CLDX remains focused on other indications for barzolvolimab.

View signal analysis

Research